# SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)

> **NCT03210480** · PHASE4 · TERMINATED · sponsor: **Aziende Chimiche Riunite Angelini Francesco S.p.A** · enrollment: 85 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Lithium sulphate prolonged-release 660 mg
- **DRUG:** Lithium carbonate immediate-release 150 mg and 300 mg

## Key facts

- **NCT ID:** NCT03210480
- **Lead sponsor:** Aziende Chimiche Riunite Angelini Francesco S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-28
- **Primary completion:** 2019-09-20
- **Final completion:** 2019-09-20
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Sponsor's decision due to slow enrollment rate.
- **Last updated:** 2020-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03210480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03210480, "SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03210480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*